BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 18591266)

  • 1. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
    Lodise TP; Graves J; Evans A; Graffunder E; Helmecke M; Lomaestro BM; Stellrecht K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3315-20. PubMed ID: 18591266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Moise PA; Smyth DS; El-Fawal N; Robinson DA; Holden PN; Forrest A; Sakoulas G
    J Antimicrob Chemother; 2008 Jan; 61(1):85-90. PubMed ID: 18042628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.
    Mascitti KB; Edelstein PH; Fishman NO; Morales KH; Baltus AJ; Lautenbach E
    Infect Control Hosp Epidemiol; 2012 Feb; 33(2):160-6. PubMed ID: 22227985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
    Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
    Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
    Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
    Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.
    Moore CL; Lu M; Cheema F; Osaki-Kiyan P; Perri MB; Donabedian S; Haque NZ; Zervos MJ
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4581-8. PubMed ID: 21825294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
    Uçkay I; Bernard L; Buzzi M; Harbarth S; François P; Huggler E; Ferry T; Schrenzel J; Renzoni A; Vaudaux P; Lew DP
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1258-64. PubMed ID: 22155824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.